Asceneuron secures $100m Series C financing to progress neurodegeneration research, Novo Holding leads round with participation from existing investor Sofinnova Partners
On Tuesday, Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation a driver of neurodegenerative disease, announced it had secured a $100 million Series C Financing that was led by Novo Holdings. This financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease.
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics, receives the Rosalind Franklin Society Special Award in Science
Vivet Therapeutics, a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, on Tuesday announced that its Co-Founder & Chief Scientific Officer, Dr Gloria Gonzalez-Aseguinolaza, PhD, has been honoured with the Rosalind Franklin Society (RFS) Special Award in Science. The prestigious award, given by Mary Ann Liebert, Inc. and the Rosalind Franklin Society, recognises Dr Gonzalez-Aseguinolaza’s remarkable contributions and dedication to advancing scientific knowledge.
4SC receives Orphan Drug Status (ODS) for resminostat (Kinselby) in cutaneous T-cell lymphoma in Switzerland
4SC AG, a biotech company improving the lives of patients suffering with advanced-stage CTCL, on Tuesday received notification from the Swiss Agency for Therapeutic Products (SwissMedic) that it has granted Orphan Drug Status to resminostat for the treatment of CTCL. Benefits include reduced fees in Switzerland and a faster review process.
Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals inn transaction valued at up to $520m
Novo Holdings A/S on Thursday announced that its portfolio company, Invetx, has agreed to be acquired by Dechra Pharmaceuticals Limited, an international veterinary pharmaceuticals business, for up to $520 million in total consideration on a cash-free and debt-free basis. Novo Holdings co-led Invetx’s Series B financing round in 2022.
Optimum TV
Fertility treatment is very common nowadays – but all too often ends in failure. In our latest episode of OptimumTV, Dr Agnès Arbat of OXOLIFE describes positive Phase 2 results for a non-hormonal pill the Spanish biotech has developed, which increases the chance of success by helping the embryo implant in the uterus.
Watch the full episode here!
That’s all folks! We hope you are enjoying Optimum’s weekly round-ups; subscribe today so you never miss an edition.
